Immune checkpoint inhibitors targeting CTLA-4, PD-1, and PD-L1 have shown promising clinical activity in patients with melanoma and, more recently, clinical activity in NSCLC across histologic subtypes [7–15]. Here, CD274 is linked to non-small cell lung carcinoma.